NewAmsterdam Pharma (NAMS) Financials: Revenue & Earnings
NAMS$21.52+0.45 +2.14%
$2.52B
Market Cap
-8.96
P/E
14.84
Forward P/E
46
Score
NewAmsterdam Pharma (NAMS) Financials: Revenue & Earnings
NAMS price $21.52 +0.45 +2.14%
- Ticker
- NAMS
- Price
- $21.52
- Change
- +0.45 +2.14%
- Market cap ?
- $2.52B
- P/E ?
- -8.96
- Forward P/E ?
- 14.84
- Dividend yield ?
- 0.00%
- Beta ?
- 0.10
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 46
- Value
- 56
- Quality
- 32
- Growth
- 50
Stocklytics score rationale: value 56, quality 32, growth 50.
Financials
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 0 | 0 | 102694000 | 14090000 | 45563000 | 22503000 |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also…
Earnings and financials
NewAmsterdam Pharma Company N.V. (NAMS) trades at $21.52, with a market cap of $2.52B and a trailing P/E of -8.96. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 0 | 0 | 102694000 | 14090000 | 45563000 | 22503000 |
Insights · Dividends · Forecast · Financials · Learn